Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2025-01-03T15:39:07.006Z Has data issue: false hasContentIssue false
  • English
  • Français

Informed Consent Issues in International Research Concerns

Published online by Cambridge University Press:  29 July 2009

Joan P. Porter
Joan P. Porter
Affiliation:
Currently with the Department of Defense, and has also recently served as the Health Research Policy Officer at the Office for Protection from Research Risks (OPRR), National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Get access Rights & Permissions [Opens in a new window]

Extract

No discussion of the informed consent process would be adequate without attention to dilemmas and challenges arising in research in foreign countries, particularly in the less developed countries. In an era of the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS), for example, much attention to research issues concerning devastating health conditions in developed and less developed countries has occurred with renewed vigor.

Type
Special Section: Issues in Consent
Information
Cambridge Quarterly of Healthcare Ethics , Volume 5 , Issue 2 , Spring 1996 , pp. 237 - 243
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Notes

1. Office of Science and Technology Policy. Federal Policy for the Protection of Human Research Subjects; Notices and Rules (5GFR28002). Washington, DC, June 18, 1991.

2. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Washington, DC, 1978.Google Scholar

3. See note 2. 1978:5

4. [Anonymous]. Journal of Law, Medicine & Health Care 1991;19:264–6.CrossRefGoogle Scholar

5. The basic elements of informed consent include: a statement that an activity involves research; an explanation of the purposes of the research and the expected duration of the subject's participation; a description of the procedures to be followed, and identification of any procedures that are‘experimental; a description of foreseeable risks and discomforts to the subject and of any benefits to the subject or to others reasonably expected from the research. There must be a disclosure of appropriate alternative procedures or courses of treatment, if any, that might be useful to the subject. A statement describing the extent to which confidentiality of records identifying the subject will be maintained. In addition, there is an explanation that participation is voluntary and that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled; the participant must also be told that he or she may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. For research that is greater than minimal risk, the extent to which compensation is available for injury must also be explained (Title 45 Code of Federal Regulations. Pt46:116; Title 21 Code of Federal Regulations. Pt50.116). The Institutional Review Board with oversight responsibility for the research can also add elements that are appropriate [45CFR, Pt46.116(b) (l)–(6)], or under certain conditions associated, in part, with minimal risk and impracticability, can modify or waive informed consent, altogether.

6. Council for International Organizations of Medical Sciences in collaboration with the World Health Organization. The International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland, 1993.Google Scholar

7. Council for International Organizations of Medical Sciences in collaboration with the World Health Organization. International Guidelines for Ethical Review of Epidemiological Studies. Geneva, Switzerland, 1991.Google Scholar

8. Council for International Organizations of Medical Sciences. 1993:13.Google Scholar

9. See note 8. CIOMS. 1993:14.Google Scholar

10. See note 8. CIOMS. 1993:15.Google Scholar

11. See note 8. CIOMS. 1993:25.Google Scholar

12. United States Congress, Office of Technology Assessment. Biomedical Ethics in United States Public Policy, 1993. Background paper OTA–BP–BBS–105. Washington, DC: United States Government Printing Office, 1993:15–17, 43–60Google Scholar; Gardner, C, Fogarty, JE. International Center for Advanced Study in Health Sciences. Compilation of international guidelines [Personal communication] 1993.Google Scholar

13. Levine, RJ. Informed consent: some challenges to the universal validity of the Western model. Law, Medicine & Health Care 1991;19:207–13CrossRefGoogle ScholarPubMed; Applying relevant international ethical principles. AIDS Research and Human Retroviruses 1993;9(Suppl): S155–6.Google Scholar

14. Angell, M. Ethical imperialism? Ethics in international collaborative clinical research. New England Journal of Medicine 1988;319:1081–3.CrossRefGoogle ScholarPubMed

15. Christakis, NA. The ethical design of an AIDS vaccine trial in Africa. Hastings Center Report 1988;June/July: 31–7.Google Scholar

16. Christakis, NA. Ethics are local: engaging cross-cultural variation in the ethics for clinical research. Social Science and Medicine 1992;35:1079–91.CrossRefGoogle ScholarPubMed

17. Nzilabi, N. Summary of international trials working group. AIDS Research and Human Retroviruses 1992;8:1433–5.Google Scholar

18. Christakis, NA, Panner, MJ. Existing international ethical guidelines for human subjects research: some open questions. Law, Medicine & Health Care 1993;19:214–21.CrossRefGoogle Scholar

19. Federal Coordinating Council on Science, Engineering, and Technology, Committee on Life Sciences and Health. The Human Immunodeficiency Virus Vaccine Challenge: Issues in Development and International Trials. Washington, DC, 07 1993.Google Scholar

20. Porter, JP, Glass, MW, Koff, WC. International AIDS vaccines. In: Blank, RH, Bonnicksen, AL, Eds. Debates Over Medical Authority: New Challenges in Biomedical Experimentation, Emerging Issues in Biomedical Policy: An Annual Review, Vol II. New York: Columbia Press.Google Scholar

21. Grady, C. The Search for an AIDS Vaccine. Bloomington and Indianapolis, Indiana: University Press, 1995.Google Scholar

22. Nowak, R. Staging ethical AIDS trials in Africa. Science Magazine 1995;269:1332–5.Google Scholar

23. Porter, L, Gostin, L. The Application of United States protections for Human Subjects Regulations and Ethical Principles to United States Funded or Conducted HIV-Related Research in Foreign Countries, Including Commentary on International Guidelines; A Comprehensive Reference Guide for Researchers and the United States Public Health Service. Washington, DC, 09 1994.Google Scholar

24. Osuntokum, BO. Individual consent: a perspective of developing countries. In: Bankowski, Z, Levine, RJ, Eds. Proceedings ofthe XXXVIth CIOMS Conference. Geneva, Switzerland, 02 5–7, 1992: 1992: 25–35.Google Scholar

25. See note 24. Osuntokum, . 1992:25–35.Google Scholar